Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Current Cancer Drug Targets
|
September 22, 2011
Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia
A Sacco, I M Ghobrial, A M Roccaro
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics
M A Dimopoulos, E Kastritis, I M Ghobrial
Journal of Biomedicine & Biotechnology
|
October 25, 2012
Bone marrow microenvironment in multiple myeloma progression
S Manier, A Sacco, X Leleu, et al.
Leukemia
|
February 23, 2018
Targeting MYC in multiple myeloma
K K Jovanović, C Roche-Lestienne, I M Ghobrial, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine
I S Batth, A Mitra, S Manier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine
I S Batth, A Mitra, S Manier, et al.
Leukemia
|
December 6, 2012
The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression
A K Azab, E Weisberg, I Sahin, et al.
Leukemia
|
December 21, 2011
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
E Weisberg, A K Azab, P W Manley, et al.
Leukemia
|
September 11, 2009
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
J P Laubach, A Mahindra, C S Mitsiades, et al.
Blood Cancer Journal
|
April 29, 2014
Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination
I Sahin, M Moschetta, Y Mishima, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Current Cancer Drug Targets
|
September 22, 2011
Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia
A Sacco, I M Ghobrial, A M Roccaro
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics
M A Dimopoulos, E Kastritis, I M Ghobrial
Journal of Biomedicine & Biotechnology
|
October 25, 2012
Bone marrow microenvironment in multiple myeloma progression
S Manier, A Sacco, X Leleu, et al.
Leukemia
|
February 23, 2018
Targeting MYC in multiple myeloma
K K Jovanović, C Roche-Lestienne, I M Ghobrial, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine
I S Batth, A Mitra, S Manier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine
I S Batth, A Mitra, S Manier, et al.
Leukemia
|
December 6, 2012
The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression
A K Azab, E Weisberg, I Sahin, et al.
Leukemia
|
December 21, 2011
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
E Weisberg, A K Azab, P W Manley, et al.
Leukemia
|
September 11, 2009
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
J P Laubach, A Mahindra, C S Mitsiades, et al.
Blood Cancer Journal
|
April 29, 2014
Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination
I Sahin, M Moschetta, Y Mishima, et al.
Page
of 2